Abstract
In type 2 diabetes (T2D), treatment is optimised to minimise hyperglycaemia and the risk of microvascular complications. While there are a number of effective treatments, intensive treatment is associated with negative side effects such as increased hypoglycaemia and weight gain. With complementary modes of action, glucagon-like peptide-1 receptor agonists (GLP-1RAs) and a basal insulin in combination offer an alternative to basal-bolus therapy in T2D. This review describes the rationale behind this treatment combination and presents clinical data available for IDegLira, the first basal insulin (insulin degludec) and GLP-1RA (liraglutide) co-formulation available in one pen for a single injection daily.
Keywords:
GLP-1; Insulin; Intensification; Type 2 diabetes.
Copyright © 2016 Primary Care Diabetes Europe. Published by Elsevier Ltd. All rights reserved.
Publication types
-
Research Support, Non-U.S. Gov't
-
Review
MeSH terms
-
Biomarkers / blood
-
Blood Glucose / drug effects
-
Blood Glucose / metabolism
-
Diabetes Mellitus, Type 2 / blood
-
Diabetes Mellitus, Type 2 / diagnosis
-
Diabetes Mellitus, Type 2 / drug therapy*
-
Diabetes Mellitus, Type 2 / physiopathology
-
Drug Combinations
-
Glucagon-Like Peptide-1 Receptor / agonists
-
Glucagon-Like Peptide-1 Receptor / metabolism
-
Glycated Hemoglobin / metabolism
-
Humans
-
Hypoglycemic Agents / administration & dosage*
-
Hypoglycemic Agents / adverse effects
-
Incretins / administration & dosage*
-
Incretins / adverse effects
-
Injections
-
Insulin Resistance
-
Insulin, Long-Acting / administration & dosage*
-
Insulin, Long-Acting / adverse effects
-
Liraglutide / administration & dosage*
-
Liraglutide / adverse effects
-
Treatment Outcome
Substances
-
Biomarkers
-
Blood Glucose
-
Drug Combinations
-
GLP1R protein, human
-
Glucagon-Like Peptide-1 Receptor
-
Glycated Hemoglobin A
-
Hypoglycemic Agents
-
Incretins
-
Insulin, Long-Acting
-
hemoglobin A1c protein, human
-
insulin degludec
-
Liraglutide